Deciphering the concepts behind "Epileptic encephalopathy" and "Developmental and epileptic encephalopathy".

Developmental and epileptic encephalopathy Developmental encephalopathy Epilepsy syndrome Epileptic encephalopathy Regression

Journal

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
ISSN: 1532-2130
Titre abrégé: Eur J Paediatr Neurol
Pays: England
ID NLM: 9715169

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 23 12 2019
accepted: 23 12 2019
pubmed: 14 1 2020
medline: 28 7 2020
entrez: 14 1 2020
Statut: ppublish

Résumé

The recent introduction of the term 'developmental and epileptic encephalopathy' by the International League Against Epilepsy has added another conceptual layer to understanding the most severe group of epilepsies. An epileptic encephalopathy is defined by the presence of frequent epileptiform activity that impacts adversely on development, typically causing slowing or regression of developmental skills, and usually associated with frequent seizures. Many of the epileptic encephalopathies are now known to have an identifiable molecular genetic basis. The term 'developmental' was introduced as there are multiple facets leading to developmental impairment in affected individuals. The underlying genetic cause often results in developmental delay in its own right, with the epileptic encephalopathy further adversely affecting development. Treatment of the epileptic encephalopathy may improve developmental progress, so early recognition and active management are essential to improve developmental outcomes. Equally, understanding that the genetic aetiology independently leads to developmental impairment means that precision therapies need to be holistic in addressing the devastating consequences of this group of diseases.

Identifiants

pubmed: 31926847
pii: S1090-3798(19)30443-X
doi: 10.1016/j.ejpn.2019.12.023
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

11-14

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

Ingrid E Scheffer (IE)

Department of Medicine and Paediatrics, The University of Melbourne, Austin Health and Royal Children's Hospital, Florey Institute and Murdoch Children's Research Institute, Melbourne, Australia. Electronic address: i.scheffer@unimelb.edu.au.

Jianxiang Liao (J)

Epilepsy Center, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH